- Home
- BNAI vs PRPO Comparison
BNAI vs PRPO Comparison
Compare BNAI & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNAI
- PRPO
- Stock Information
- Founded
- BNAI 2018
- PRPO N/A
- Country
- BNAI United States
- PRPO United States
- Employees
- BNAI N/A
- PRPO N/A
- Industry
- BNAI
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- BNAI
- PRPO Industrials
- Exchange
- BNAI NYSE
- PRPO Nasdaq
- Market Cap
- BNAI 20.7M
- PRPO 17.1M
- IPO Year
- BNAI N/A
- PRPO N/A
- Fundamental
- Price
- BNAI $0.34
- PRPO $14.45
- Analyst Decision
- BNAI Strong Buy
- PRPO
- Analyst Count
- BNAI 1
- PRPO 0
- Target Price
- BNAI $6.00
- PRPO N/A
- AVG Volume (30 Days)
- BNAI 824.9K
- PRPO 17.7K
- Earning Date
- BNAI 08-13-2025
- PRPO 08-12-2025
- Dividend Yield
- BNAI N/A
- PRPO N/A
- EPS Growth
- BNAI N/A
- PRPO N/A
- EPS
- BNAI N/A
- PRPO N/A
- Revenue
- BNAI $60,000.00
- PRPO $20,029,000.00
- Revenue This Year
- BNAI N/A
- PRPO N/A
- Revenue Next Year
- BNAI N/A
- PRPO N/A
- P/E Ratio
- BNAI N/A
- PRPO N/A
- Revenue Growth
- BNAI N/A
- PRPO 26.67
- 52 Week Low
- BNAI $0.23
- PRPO $3.90
- 52 Week High
- BNAI $3.74
- PRPO $16.89
- Technical
- Relative Strength Index (RSI)
- BNAI 45.68
- PRPO 68.17
- Support Level
- BNAI $0.34
- PRPO $14.25
- Resistance Level
- BNAI $0.39
- PRPO $16.89
- Average True Range (ATR)
- BNAI 0.04
- PRPO 1.08
- MACD
- BNAI -0.00
- PRPO 0.24
- Stochastic Oscillator
- BNAI 28.52
- PRPO 67.57
About BNAI BRAND ENGAGEMENT NETWORK INC
Brand Engagement Network Inc is a generative AI (GenAI) company specializing in conversational AI solutions. Through its secure, human-like AI agents, available in different modalities, the company seeks to transform consumer engagement and elevate customer experience, productivity, and business performance.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.